Followers | 145 |
Posts | 27561 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Thursday, September 03, 2020 12:52:49 PM
By Kate Hudson -September 3, 2020
Throughout its many years of operation, Can-Fite Biopha (NYSEAMERICAN:CANF) has been addressing multi-billion dollar markets. Its primary target has been the advancement of cancer treatments, inflammatory diseases, and, most recently, COVID-19. A majority of the company’s drugs have demonstrated an excellent safety profile, having been used in over 1,500 patients in clinical studies to date.
Can-Fite continues to count its milestones after receiving a notification of its intent to grant a patent for Namodenoson in the Treatment of non-alcoholic steatohepatitis (NASH) from the European Patent Office. The patent was justified by a strong safety profile demonstrated by Namodenoson and the fact that it also met in the Treatment of NASH and non-alcoholic fatty liver disease (NAFLD).
Licensing and Distribution Agreements for Namodenoson
NAFLD and NASH are some of the heaviest disease burdens in Europe today. Epidemiology studies indicate that the two’s dominance stands between 29-37% and 16-45%, respectively, among the general population. This is a worrisome situation, indeed. Having completed a Phase II study and with the patent notification, Dr. Pnina Fishman, the CEO of Can-Fite BioPharma, says that it is the high time looked for potential distribution partners.
The Israeli-based company has been collaborating with some of the largest researchers from the US NIH and also from the Leiden University in the Netherlands. Meanwhile, patents for Namodenoson will be in Korea and the US. Can-Fite has also received licensing and distribution agreements for Namodenoson in China.
The Licensing of Piclidenoson for the Treatment of Autoimmune Diseases
Piclidenoson (CF101) is an oral drug and has undergone successful testing in animal models. The drug has been indicated as a disease-modifying anti-inflammatory drug in Rheumatoid Arthritis (RA) patients from two Phase II studies. The says it has dosed over 1,400 patients with the drug in prior trials, and after a 28-day study with 40 patients on board, Piclidenoson has been cleared for a Phase II study in the Treatment of COVID-19.
This is a pilot trial in a population of hospitalized patients and will be assessing efficacy through standard measures of clinical and respiratory status. The drug is expected to be an ideal candidate in treating the complications of COVID-19, given its unique combination of anti-inflammatory effect.
https://biopharmajournal.com/2020/09/03/the-european-patent-office-notifies-can-fite-biopha-nyseamericancanf-of-its-patent-grant-for-namodenoson-in-the-treatment-of-nash/
Recent CANF News
- Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal • Business Wire • 04/25/2024 11:00:00 AM
- Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH • Business Wire • 04/15/2024 11:00:00 AM
- Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients • Business Wire • 04/03/2024 11:00:00 AM
- Can-Fite Reports 2023 Financial Results and Clinical Update • Business Wire • 03/28/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/11/2024 11:27:14 AM
- Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference • Business Wire • 03/11/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/28/2024 12:06:42 PM
- Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada • Business Wire • 02/28/2024 12:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:32:17 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/30/2024 12:24:02 PM
- Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication • Business Wire • 01/30/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/29/2024 12:05:47 PM
- Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study • Business Wire • 01/29/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/08/2024 05:15:13 AM
- Form F-3/A - Registration statement by foreign private issuers: [Amend] • Edgar (US Regulatory) • 12/28/2023 09:16:08 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/20/2023 12:09:12 PM
- The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies • Business Wire • 12/20/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/18/2023 12:07:51 PM
- Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan • Business Wire • 12/18/2023 12:00:00 PM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 12/12/2023 09:15:49 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/04/2023 12:05:03 PM
- Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development • Business Wire • 12/04/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/30/2023 12:05:42 PM
- Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update • Business Wire • 11/30/2023 12:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/22/2023 09:20:47 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM